Chimeric CD7 monoclonal antibody therapy in rheumatoid arthritis.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 1279168.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Murine monoclonal antibody (Mab) therapy in patients with rheumatoid arthritis (RA) produces an antimouse immunoglobulin response by the recipient. We studied a chimeric (human/mouse) CD7 Mab, in a dose ranging tolerability study in 10 patients with RA. Modest improvements in disease activity occurred with frequent acute adverse effects of malaise, fever and nausea. After treatment, peripheral blood T lymphocyte numbers fell by 50% and CD7 expression fell by 97% for less than 7 days. Our study demonstrates chimeric Mab function in vivo and illustrates the influence of antibody isotype and patient characteristics on adverse effects.
Medical subject headings
- Antibodies, Monoclonal
- Antigens, CD
- Antigens, Differentiation, T-Lymphocyte
- Arthritis, Rheumatoid
- Recombinant Fusion Proteins